Cutera, Inc. (NASDAQ:CUTR) has earned a consensus recommendation of “Hold” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $45.00.
CUTR has been the topic of a number of recent research reports. BidaskClub upgraded Cutera from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 5th. ValuEngine lowered shares of Cutera from a “buy” rating to a “hold” rating in a research report on Tuesday. Maxim Group restated a “hold” rating on shares of Cutera in a research note on Friday, August 9th. Stephens lifted their price objective on shares of Cutera from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Finally, Zacks Investment Research downgraded shares of Cutera from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th.
Cutera stock traded up $0.38 during trading hours on Wednesday, hitting $37.47. 152,483 shares of the stock traded hands, compared to its average volume of 171,898. The firm’s 50 day moving average price is $34.30 and its 200-day moving average price is $27.26. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.66 and a quick ratio of 1.05. The stock has a market capitalization of $533.31 million, a price-to-earnings ratio of -16.80 and a beta of 0.96. Cutera has a 1 year low of $12.32 and a 1 year high of $39.15.
Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Thursday, November 7th. The medical device company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.23. Cutera had a negative return on equity of 84.67% and a negative net margin of 20.84%. The firm had revenue of $46.12 million during the quarter, compared to analysts’ expectations of $41.66 million. During the same period last year, the business posted $0.11 earnings per share. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. Research analysts forecast that Cutera will post -0.71 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC purchased a new position in shares of Cutera during the 2nd quarter valued at about $31,000. First Quadrant L P CA purchased a new stake in shares of Cutera in the third quarter worth about $51,000. Quantamental Technologies LLC purchased a new stake in shares of Cutera in the second quarter worth about $37,000. JPMorgan Chase & Co. boosted its stake in shares of Cutera by 14.6% in the second quarter. JPMorgan Chase & Co. now owns 3,798 shares of the medical device company’s stock worth $76,000 after buying an additional 483 shares during the last quarter. Finally, Eqis Capital Management Inc. acquired a new stake in Cutera during the third quarter worth about $278,000. 91.46% of the stock is currently owned by institutional investors.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.